Traders assign a 93% probability against a new COVID variant of concern emerging before 2027 because no SARS-CoV-2 lineage currently meets WHO or ECDC criteria for that designation, even after extensive genomic tracking of Omicron subvariants. Recent surveillance through mid-2026 shows strains like BA.3.2 (nicknamed Cicada), NB.1.8.1, and XFG circulating at notable levels in wastewater and sequences yet producing no meaningful rise in severity, transmissibility, or immune escape that would trigger reclassification. Dominant lineages such as XFG.1.1 continue evolving modestly without crossing public-health thresholds, while overall case incidence and emergency visits remain very low. Updated 2026-2027 vaccine formulations target these same lineages, underscoring the view that the virus has entered a phase of incremental drift rather than disruptive shifts likely to prompt a formal variant-of-concern label in the remaining months of the year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
$243,750 Vol.
$243,750 Vol.
Oui
$243,750 Vol.
$243,750 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Marché ouvert : Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Traders assign a 93% probability against a new COVID variant of concern emerging before 2027 because no SARS-CoV-2 lineage currently meets WHO or ECDC criteria for that designation, even after extensive genomic tracking of Omicron subvariants. Recent surveillance through mid-2026 shows strains like BA.3.2 (nicknamed Cicada), NB.1.8.1, and XFG circulating at notable levels in wastewater and sequences yet producing no meaningful rise in severity, transmissibility, or immune escape that would trigger reclassification. Dominant lineages such as XFG.1.1 continue evolving modestly without crossing public-health thresholds, while overall case incidence and emergency visits remain very low. Updated 2026-2027 vaccine formulations target these same lineages, underscoring the view that the virus has entered a phase of incremental drift rather than disruptive shifts likely to prompt a formal variant-of-concern label in the remaining months of the year.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour



Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes